Background and Study Aims: We aim to determine the frequency of thymidylate synthase (TS) and excision repair cross-complementation group 1 (ERCC-1) immunohistochemical (IHC) expression and its relationship with clinicopathologic variables in colorectal carcinoma (CRC) patients. In addition, we aim to assess the correlation between TS and ERCC-1 expression and the response of these cases to oxaliplatin and 5-fluorouracil chemotherapy (FOLFOX). Patients and Methods: Fifty-one CRC patients were prepared for IHC analysis of ERCC-1 and TS protein expression. All patients received oxaliplatin and 5-fluorouracil combined chemotherapy (FOLFOX) and were followed up for 24 months. Results: The data analysis showed that high ERCC-1 and TS expression was significantly associated with early treatment failure (P=0.020 and 0.000). In contrast, TS immunoexpression affects the disease-free survival rate (P=0.010). The presence of deep tumor invasion, distant metastasis, lymph node metastasis, and high Dukes’ classification were significantly statistically associated with early treatment failure (P=0.001, 0.000, 0.041, and 0.015, respectively). Conclusions: Our results showed that both ERCC-1 and TS are predictive factors for early treatment failure in CRC patients. TS protein is a prognostic factor for disease-free survival rates. This supports the theory that both ERCC-1 and TS can be used to improve chemotherapeutic outcomes in CRC patients. High expression of TS and ERCC-1 helps in the identification of cases that will get fewer benefits from FOLFOX chemotherapy. As an innovative strategy, in these cases, we can use alternative chemotherapeutic regimens or add an extra agent. In addition, Dukes’ classification and lymph node metastasis are predictive factors for early treatment failure. Thus, all those values can be used to predict CRC patients with bad prognosis and those who will get fewer benefits from FOLFOX.

中文翻译：

---

切除修复交叉互补组 1 和胸苷酸合成酶对接受 FOLFOX 化疗的结直肠癌患者的预后和预测作用

背景和研究目的：我们旨在确定胸苷酸合酶 (TS) 和切除修复交叉互补组 1 (ERCC-1) 免疫组织化学 (IHC) 表达的频率及其与结直肠癌 (CRC) 患者临床病理变量的关系。此外，我们旨在评估 TS 和 ERCC-1 表达与这些病例对奥沙利铂和 5-氟尿嘧啶化疗 (FOLFOX) 反应之间的相关性。患者和方法：准备 51 名 CRC 患者进行 ERCC-1 和 TS 蛋白表达的 IHC 分析。所有患者均接受奥沙利铂和5-氟尿嘧啶联合化疗（FOLFOX），随访24个月。结果：数据分析表明，ERCC-1和TS的高表达与早期治疗失败显着相关（P=0.020和0.000）。相比之下，TS 免疫表达影响无病生存率 (P=0.010)。肿瘤深部浸润、远处转移、淋巴结转移和高杜克斯分类的存在与早期治疗失败显着相关（分别为 P=0.001、0.000、0.041 和 0.015）。结论：我们的结果表明 ERCC-1 和 TS 都是 CRC 患者早期治疗失败的预测因素。TS 蛋白是无病生存率的预后因素。这支持了 ERCC-1 和 TS 均可用于改善 CRC 患者化疗结果的理论。TS 和 ERCC-1 的高表达有助于识别从 FOLFOX 化疗中获益较少的病例。作为一种创新策略，在这些情况下，我们可以使用替代化疗方案或添加额外的药物。此外，Dukes 分类和淋巴结转移是早期治疗失败的预测因素。因此，所有这些值都可用于预测预后不良的 CRC 患者以及从 FOLFOX 中获益较少的患者。